Want to see IN:SUNPHARMA full AI Analyst Report?

Sun Pharmaceutical Industries Limited (SUNPHARMA) Price & Analysis

21 Followers

SUNPHARMA Stock Chart & Stats

₹1941.00

₹32.60(1.68%)

At close: Jul 27 4:00 PM EDT

₹1941.00

₹32.60(1.68%)

Day’s Range― - ―

52-Week Range₹1,547.25 - ₹2,047.55

Previous CloseN/A

Volume5.41M

Average Volume (3M)102.58K

Market Cap

₹4.56T

Enterprise Value₹3.93M

Total Cash (Recent Filing)₹335.17B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)37.7

Beta0.51

Next Earnings

Nov 03, 2026

EPS Estimate

12.46

Next Dividend Ex-DateN/A

Dividend Yield0.84%

Share Statistics

EPS (TTM)50.41

Shares Outstanding2,399,278,300

10 Day Avg. Volume56,056

30 Day Avg. Volume102,581

Financial Highlights & Ratios

PEG Ratio7.62

Price to Book (P/B)5.05

Price to Sales (P/S)7.22

P/FCF Ratio45.66

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)54.05

Revenue Forecast (FY)₹648.50B

Bulls Say, Bears Say

Bulls Say

Multi-year Revenue GrowthSustained revenue growth indicates continued demand across Sun Pharma’s branded generics, generics, and specialty portfolio. Its diversified therapeutic and geographic presence can support durable expansion and reduce reliance on any single market.

Stable Net ProfitabilityConsistently strong net margins suggest the company retains meaningful earnings power despite operating in competitive pharmaceutical markets. This profitability provides resources to fund product development, regulatory compliance, and commercial investment.

Conservative Balance SheetVery low leverage limits interest and refinancing risk while preserving financial flexibility. The steadily expanding equity and asset base also strengthens resilience, allowing Sun Pharma to invest in manufacturing, pipeline development, and strategic growth.

Bears Say

Sharp Gross Margin PressureThe steep gross-margin decline signals potential cost, product-mix, pricing, or competitive pressure. If persistent, it could constrain reinvestment capacity and weaken the earnings contribution from otherwise healthy revenue growth.

Weak Earnings-to-cash ConversionRepeatedly lower operating cash flow than net income points to working-capital or timing headwinds and reduces the quality of reported earnings. Continued volatility could limit internally funded investment even though free cash flow remains positive.

Uneven Capital EfficiencyLow leverage improves financial safety but can also make returns on equity more dependent on operating efficiency. Historically uneven ROE suggests Sun Pharma may not generate best-in-class returns from its growing equity and asset base.

Sun Pharmaceutical Industries Limited News

Sun Pharma Wins Key U.S. Appeal in Lipitor Antitrust Case

Sun Pharmaceutical Industries Limited ( ($IN:SUNPHARMA) ) just unveiled an update. Sun Pharmaceutical Industries Limited and certain subsidiaries...

8d ago

Sun Pharma Shareholders Clear All Resolutions at 34th AGM, Approve Dividend and Board Changes

Sun Pharmaceutical Industries Limited ( ($IN:SUNPHARMA) ) has shared an update. Sun Pharmaceutical Industries Limited convened its 34th...

24d ago

Sun Pharma’s Partner Philogen Resubmits EMA Application for Melanoma Drug Nidlegy

An announcement from Sun Pharmaceutical Industries Limited ( ($IN:SUNPHARMA) ) is now available. Sun Pharmaceutical Industries Limited has...

29d ago

Sun Pharma Clears Key Hurdle as Organon Shareholders Approve Acquisition

Sun Pharmaceutical Industries Limited ( ($IN:SUNPHARMA) ) just unveiled an announcement. Sun Pharma said shareholders of Organon &...

1M ago

Sun Pharma wins South African nod for generic semaglutide

Sun Pharmaceutical Industries Limited ( ($IN:SUNPHARMA) ) has provided an announcement. Sun Pharma has received approval from the...

1M ago

Sun Pharma to Acquire Innovcare Lifesciences for Rs 271 Crore

Sun Pharmaceutical Industries Limited ( ($IN:SUNPHARMA) ) has provided an update. Sun Pharmaceutical Industries Limited has agreed to...

2M ago

Sun Pharma shareholders approve postal ballot, appoint new independent director

Sun Pharmaceutical Industries Limited ( ($IN:SUNPHARMA) ) just unveiled an announcement. Sun Pharmaceutical Industries Limited has completed a...

4M ago

Sun Pharma Releases Investor Call Transcript on Organon Business Acquisition

Sun Pharmaceutical Industries Limited ( ($IN:SUNPHARMA) ) has shared an announcement. Sun Pharmaceutical Industries Limited has notified the...

4M ago

Sun Pharma to Buy Organon in US$ 11.75 Billion All‑Cash Deal

Sun Pharmaceutical Industries Limited ( ($IN:SUNPHARMA) ) has provided an update. Sun Pharmaceutical Industries has signed a definitive...

4M ago

Sun Pharma to Host Investor Call on Organon Acquisition

Sun Pharmaceutical Industries Limited ( ($IN:SUNPHARMA) ) just unveiled an update. Sun Pharmaceutical Industries has scheduled an investor...

4M ago

SUNPHARMA FAQ

What was Sun Pharmaceutical Industries Limited’s price range in the past 12 months?

Sun Pharmaceutical Industries Limited lowest stock price was ₹1547.25 and its highest was ₹2047.55 in the past 12 months.

What is Sun Pharmaceutical Industries Limited’s market cap?

Sun Pharmaceutical Industries Limited’s market cap is ₹4.56T.

When is Sun Pharmaceutical Industries Limited’s upcoming earnings report date?

Sun Pharmaceutical Industries Limited’s upcoming earnings report date is Nov 03, 2026 which is in 70 days.

How were Sun Pharmaceutical Industries Limited’s earnings last quarter?

Sun Pharmaceutical Industries Limited released its earnings results on Jul 31, 2026. The company reported ₹12.7 earnings per share for the quarter, beating the consensus estimate of ₹12.525 by ₹0.175.

Is Sun Pharmaceutical Industries Limited overvalued?

According to Wall Street analysts Sun Pharmaceutical Industries Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sun Pharmaceutical Industries Limited pay dividends?

Sun Pharmaceutical Industries Limited pays a Semiannually dividend of ₹5 which represents an annual dividend yield of 0.84%. See more information on Sun Pharmaceutical Industries Limited dividends here

What is Sun Pharmaceutical Industries Limited’s EPS estimate?

Sun Pharmaceutical Industries Limited’s EPS estimate is 12.46.

How many shares outstanding does Sun Pharmaceutical Industries Limited have?

Sun Pharmaceutical Industries Limited has 2,399,278,300 shares outstanding.

What happened to Sun Pharmaceutical Industries Limited’s price movement after its last earnings report?

Sun Pharmaceutical Industries Limited reported an EPS of ₹12.7 in its last earnings report, beating expectations of ₹12.525. Following the earnings report the stock price went down -0.57%.

Which hedge fund is a major shareholder of Sun Pharmaceutical Industries Limited?

Currently, no hedge funds are holding shares in IN:SUNPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical enterprise, is dedicated to the research, development, production, and marketing of both proprietary and unbranded medicinal formulations, alongside active pharmaceutical ingredients (APIs), for distribution across India and international markets. Its extensive product range encompasses treatments for numerous therapeutic fields, including central nervous system disorders, dermatological conditions, cardiovascular diseases, oncology, ophthalmic care, neuropsychiatry, gastrointestinal issues, infectious diseases, diabetes management, pain relief, nutritional supplements, respiratory ailments, gynaecology, urology, orthopaedics, nephrology, and dental health, among others. The company additionally provides APIs crucial for the creation of anti-cancer drugs, peptides, steroids, sex hormones, and controlled substances. Its generic medications are available in various forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquid preparations. Furthermore, Sun Pharma develops specialized medications and a variety of over-the-counter health products. The company was established in 1983 and operates from its headquarters in Mumbai, India.